Patient Segmentation in Pharma: From Epidemiology to Media
How pharma segments patients by clinical profile, journey stage, and needs, and how to turn segments into privacy-safe media audiences.
The short answer
Patient segmentation in pharma groups patients by clinical profile (severity, treatment history), journey stage (undiagnosed, newly diagnosed, on therapy), and needs or attitudes. It starts with epidemiology to size each group, uses research to understand needs, and becomes media through privacy-safe audiences such as condition-interest, contextual, and modeled segments rather than identified patient data.
DTC teams often jump straight to personas: "Busy Brenda, 52, manages her diabetes between work and family." Personas help creative teams, but they are the last step, not the first. Useful patient segmentation starts with how many patients are in each situation and what they need.
Three ways to segment patients
| Approach | Example segments | Main data |
|---|---|---|
| Clinical | Mild, moderate, severe; treatment-naive vs experienced | Claims, EHR, epidemiology |
| Journey stage | Undiagnosed, newly diagnosed, on therapy, discontinued | Claims, research |
| Needs and attitudes | Wants control, fears side effects, cost-sensitive | Surveys, social listening |
Most brands combine a clinical or journey frame with needs-based groups inside it.
Step 1: Size with epidemiology
Start with how many patients are in each clinical or journey group. Sources include published epidemiology, claims analysis, and syndicated data. Sizing tells you where the opportunity is. A large "undiagnosed" group may call for disease awareness; a large "discontinued" group may call for adherence and support.
Step 2: Understand needs
Research explains why patients in each group behave as they do. Interviews and surveys reveal barriers: fear of injections, cost, not knowing a treatment exists, not wanting to bother the doctor. The patient journey mapping article shows how to organize these by stage.
Step 3: Make segments targetable
This is where privacy matters most. Identified patient medical data cannot simply be used to target ads. Common compliant routes:
- Condition-interest audiences built from consumer behavior signals, with health sensitivity rules. See ailment audience targeting.
- Contextual targeting on content about the condition.
- Modeled audiences built from de-identified data under privacy review.
- Opt-in programs where patients register for support.
- Caregiver audiences where caregivers make decisions. See caregiver strategy.
State laws, such as Washington's My Health My Data Act, add consent requirements for consumer health data. Check with privacy counsel before activating any health-related audience.
Step 4: Assign messages and channels
| Segment | Likely message | Likely channels |
|---|---|---|
| Undiagnosed with symptoms | Recognize symptoms, talk to a doctor | Search, contextual, CTV |
| Newly diagnosed | Treatment options, questions to ask | Search, condition sites, social |
| On therapy, struggling | Support, persistence | Owned channels, CRM, retargeting where allowed |
| Discontinued | Reasons to revisit with doctor | Owned channels, contextual |
Measuring by segment
Measure each segment against its goal. Awareness for undiagnosed, conversation starters for newly diagnosed, refills for on-therapy. Rolling them into one campaign KPI hides what is working.
Common mistakes
- Building personas before sizing segments.
- Assuming a segment is targetable because it is easy to describe.
- Using sensitive health data without privacy review.
- One message for every journey stage.
Practical takeaway
List your patient segments with three columns: size, main barrier, and how you will reach them compliantly. Any segment without a credible answer in the third column needs a different approach, such as contextual or owned channels.
Frequently asked questions
What are patient segments in pharma?
Groups of patients who share clinical characteristics, journey stage, or needs, and so need a different message, channel, or support approach.
Can pharma target patients by diagnosis?
Not with identified medical records for advertising. Brands use privacy-compliant alternatives: de-identified and modeled audiences, contextual targeting, and opt-in programs, within HIPAA, FTC, and state law.
What is a patient persona?
A short, research-based description of a typical patient in a segment, used to guide creative and channel choices. It should be grounded in data, not invented.
Sources
- HHS, Guidance Regarding Methods for De-identification of PHI
- FTC, Health Breach Notification Rule: The Basics for Business
- Washington State Office of the Attorney General, Protecting Washingtonians' Personal Health Data and Privacy
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.